Anti-tumor medicine in double-aryl urea structure based on indazole, indole, azaindazole or azaindole

Abstract

The invention belongs to the field of medicines, relates to anti-tumor medicines, and in particular relates to anti-tumor medicines in double-aryl urea structures based on indazole, indole, azaindazole or azaindole. The structural formulae of the anti-tumor medicines are shown in formula (Ia) and formula (Ib), wherein Z is N atom or C atom; W is O; M is O, S, N or CH; n is 1 or 2; Y and R are halogen atoms, H, R1, CF3, OCF3, OH, OR2, OCOR3, NH2, NHR4, NR52, NHCOR6, carboxyl group, ester group, cyano group, mercapto group, alkyl sulphanyl, sulfuryl, sulfoxide, sulfonic group, sulfamate, sulfonamide, ketonic group, aldehyde group, nitro group or nitroso group. Pharmacodynamic experiments prove that the medicines have good anti-tumor effects on human lung cancer, human kidney cancer, human colon cancer, human liver cancer, human gastric cancer, human breast cancer, melanoma and the like.

Description

technical field

[0001] The invention belongs to the field of medicines, and relates to a class of antineoplastic drugs, in particular to an antineoplastic drug based on indazole, indole or azaindazole, azaindole bisaryl urea structure. Pharmacological experiments have proved that these drugs have good anti-tumor effects on human breast cancer, human liver cancer, human kidney cancer, human colon cancer, human gastric cancer, human lung cancer, and melanoma. Background technique

[0002] According to statistics, there are as many as 12 million cancer patients diagnosed in the world, and more than 7 million patients die of cancer every year. Cancer has become one of the deadliest diseases in the world.

[0003] Renal cell carcinoma (RCC), a form of kidney cancer arising from renal tubular cells, accounts for 90-95% of kidney tumors and approximately 2% of adult malignancies. Renal cell carcinoma is the sixth leading cause of cancer death, with an estimated 95,000 deaths worl...

Images